Press Room

Latest

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001


News - 2006

Director Appointment

December 1st, 2006

Uscom Limited (ASX Code: UCM) today announced the appointment of Mr Bruce Rathie as an independent non-executive director of the company.

With a background in law, investment banking and business management, Mr Rathie, aged 51, is a highly skilled professional director, and offers valuable corporate skills for the next steps in Uscom’s strategic development.

Mr Rathie is currently the National Executive Director of the Australian Institute of Management and holds degrees in law, commerce and business. He is a Fellow of both the Australian Institute of Company Directors and the Australian Institute of Management. He holds Diplomas from the AICD and from Chartered Secretaries Australia.

Commenting on the appointment today, the Chairman of Uscom, Mr Rob Phillips said, “Uscom is at an important turning point, with opportunities for big changes during the coming year. Bruce Rathie is a perfect fit for our company, both as a professional company director and with extensive experience in international deal making. We are delighted to welcome Mr Rathie to the Uscom team at a critical time in the company’s history.”

Mr Rathie said, “I am delighted to be given the opportunity to join the Board of Uscom. The company is at an exciting point in its development having successfully launched its products into international markets. I look forward to assisting the company transition into a major player in the medical devices sector.”

About Bruce Rathie: Mr Rathie holds degrees in law, commerce and business and has considerable experience as a lawyer having practiced as a solicitor and partner in a major Brisbane based legal firm and then as Senior in-house Counsel to Bell Resources Limited from 1980 to 1985 in aggregate. He studied for his MBA in Geneva and then went into investment banking in 1986 which subsequently took him to New York for over 2 years returning to Sydney in 1990. He spent the 90‘s in investment banking in Sydney, the last 5 years of which as a Director of Investment Banking at Salomon Brothers/ Salomon Smith Barney where he was responsible for the firm‘s activities/ roles in the industrial sector and the Federal Government‘s privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1).

Mr Rathie has been in business since 2000 and currently is, in addition to his part time role as National Executive Director of the Australian Institute of Management, a non-executive director of Compumedics Limited, Chairman of BioLayer Corporation Limited, a non-executive director of PolyNovo Biomaterials Pty. Ltd., DataTraceDNA Pty Ltd & Carbon Energy Pty Ltd being joint ventures between CSIRO and ASX listed companies and Chairman of UnitingCare Ageing NSW & ACT, one of the largest aged care service providers in NSW.

U.S. Publication: USCOM & Hemodynamics “Improved assessment, Greater Ease & Increased Safety, Treatments in a timely manner, Safe, easy to use, easy to learn & accurate”

November 30th, 2006

Uscom Limited (ASX Code: UCM) today announced the publication of a peer-reviewed paper in the United States, reinforcing the role of Uscom in hemodynamics management.

The paper, authored by Dr Tom Ahrens, was published in “Advanced Critical Care”, an official quarterly publication of the American Association of Critical-Care Nurses. In his paper titled, “Hemodynamics in Sepsis”, Dr Ahrens stressed the importance of non-invasive monitoring, stating, “The identification of the hemodynamic state is essential to optimally treating the patient.”

“Fortunately, hemodynamic monitoring techniques are markedly improved from older techniques such as the pulmonary artery catheter. This improved assessment should make it much easier to properly identify sepsis and initiate appropriate treatments in a timely manner.” The paper cites four case studies in which traditional assessment methods were shown to be unreliable indicators for therapy. Dr Ahrens referred to an Uscom device as an example of an ideal technology which was safe, easy to use, easy to learn and accurate. He stated, “Less invasive or non-invasive devices, for example, external or esophagael Doppler, are likely to dominate practice because of ease of use; they are relatively inexpensive, rapid and accurate.”

In the paper’s summary, Dr Ahrens stated, “Helping the clinicians evaluate hemodynamic changes seen in sepsis are new technologies, for example, noninvasive Doppler, that allow hemodynamic monitoring to be performed on more patients, with greater ease and increased safety. As hemodynamic monitoring improves, improved assessment of patients with all forms of hemodynamic disturbances, including sepsis is possible. Improved monitoring will lead to more precise assessment and administration of treatments, holding the promise of improved patient outcome and reducing resource utilization.”

Dr Ahrens’ paper is the 8th peer-reviewed publication highlighting Uscom’s role in medical practice.

In total, more than 50 papers have been presented or published on the Uscom technique, with 28 presented since July 2006.

About Tom Ahrens, DNS, RN, CS, FAAN

Dr. Ahrens is a noted authority in critical care, specializing in hemodynamics, pulmonary and tissue oxygenation. He is a practising clinical nurse specialist with 24 years experience and is a recognized leader in the field of nurse education. Author of four books, Hemodynamic Waveform Analysis is considered by many to be one of the finest clinical guides to the topic and Essentials of Oxygenation was selected as an American Journal of Nursing Book of the Year. The primary author on over 50 papers, he currently is on the editorial board of American Journal of Critical Care and the Journal of Cardiovascular Nursing. He was awarded a 1999 Society of Critical Care Medicine “Presidential Citation” and an AACN 1999 research abstract award for his work on sedation.Dr. Ahrens is currently active in research on end of life management, predicting survival during cardiopulmonary arrests, the use of technology and the value expert clinicians play in improving patient outcome while controlling costs.

Further USCOM Evidence in ED “Marked benefit in monitoring response to therapy”

November 24th, 2006

USCOM Limited (ASX Code: UCM) today announced the presentation of new scientific evidence for USCOM’s role in the diagnosis and management of Sepsis in Emergency medicine.

A new study, conducted at the Emergency Department of Sydney’s Prince of Wales Hospital, was presented yesterday at the 23rd annual scientific meeting of the Australasian College for Emergency Medicine in Sydney.

The study, led by Dr Paul Middleton, used USCOM to assess the haemodynamic status of patients under-going standard treatment for varying degrees of Sepsis Syndrome.

The study concluded “Doppler ultrasound derived variables identified underlying pathophysiological patterns in cardiovascular dysfunction and also showed marked benefit in monitoring response to therapy.”

The Prince of Wales study was the 27th presentation of USCOM scientific evidence since July.

Commenting on the new presentation today, the Chief Executive of USCOM, Mr Gary Davey said, “Dr Middleton’s study provides compelling evidence that USCOM has a significant role to play in emergency care. Clinicians are able to supplement their routine procedures with a completely non-invasive examination with USCOM to help in both diagnosis and therapy management.”

Dr Middleton is a member of the faculty of the University of New South Wales School of Public Health and Community Medicine and is a Senior Lecturer in the Department of Anaesthetics, Emergency Medicine & Intensive Care at the Prince of Wales Clinical School at Randwick in Sydney.

Dr Middleton Abstract (.pdf 65kb)

Annual General Meeting “Discussions for strategic alliances” Resolutions adopted as presented

November 24th, 2006

USCOM Limited (ASX Code: UCM) today presented an update on the company’s operations at the Annual General Meeting of shareholders in Sydney.

In his presentation to shareholders, the Chairman of USCOM, Mr Rob Phillips announced the company was in discussion with a number of international companies regarding strategic alliances in Europe and the United States. The company was also in discussion with professional advisers in the U.S. following the incorporation of USCOM Inc, the company’s new North American subsidiary.

In addition, the company was currently recruiting 2 new independent non-executive directors, with international deal-making as key skill sets for these appointments

Among the milestones reported to the meeting were:

Mr Phillips said, “USCOM remains focused on its core priorities, carefully managing resources and poised for significant change in both its structure and operations. We are determined to build a valuable global business with sound foundations such as universal regulatory approval and robust patent protection. USCOM is very close to “the tipping point”, we are gaining traction in sales and we have profitability within our sights.”

The Annual General Meeting considered 3 resolutions, concerning election of directors, the directors’ remuneration report and a resolution for an amendment to the company constitution providing for the sale of non-marketable parcels of shares.

Each of the resolutions was adopted as presented.

The presentations to shareholders at the Annual General Meeting are available for download here:

AGM presentations (.pdf 1286kb)

USCOM wins Deloitte Technology Fast 50 Award “Exceptional growth” “Future looking very bright for USCOM”

November 23rd, 2006

USCOM Limited (ASX Code: UCM) announced today it had received a Deloitte Technology Fast 50 Award The Deloitte Technology Fast 50 ranks the 50 fastest growing Australian technology companies, public or private, based on percentage revenue growth over three years (2004 to 2006) and includes all related industry sectors: communications; software; semiconductors; components and electronics; life sciences; internet; and computer peripherals. USCOM was one of 8 companies in the Biotechnology and Pharmaceutical category of the awards, achieving 191% per cent revenue growth over the last three years.

USCOM is a Sydney-based medical devices company that specialises in sophisticated non-invasive monitoring of heart function, based on proven ultrasound technology. Its first instrument to be commercialised is the USCOM cardiac output monitor, a patent protected, custom-designed patient management tool for the optimisation of cardiac blood flow.

The Chief Executive of USCOM, Mr Gary Davey said “We are delighted to have received this recognition from Deloitte. It comes at a time when our company is going through an important transition, having achieved a critical mass of evidence and ready for the next major steps in our development.”

Deloitte Technology, Media and Telecommunications partner, Ms Julia Bickerstaff, said the growth of USCOM had been astounding. “Managing growth is challenging for many organisations, but USCOM has achieved exceptional growth during a downturn in the technology sector.

“With the global tech sector recovery, Australia is leading the region and the future is looking very bright for USCOM”

USCOM ANNOUNCES U.S. SUBSIDIARY

November 16th, 2006

USCOM Limited (ASX Code: UCM) today announced the incorporation of USCOM Inc in the United States, the company’s first overseas subsidiary.

Incorporated in the State of Delaware, USCOM Inc has been established as the company’s vehicle for operations in North America.

Commenting today, the Chief Executive of USCOM, Mr Gary Davey said, “The United States will be USCOM’s single biggest market and is a strategic priority for the growth and development of our company. We believe it is the right time to incorporate in the US in anticipation of significant commercial opportunities in the market.”

USCOM’s first and primary patent was recorded at the US Patent Attorney’s Office in May 2003, followed by a 510K regulatory clearance from the US Food & Drug Administration (FDA) in February 2005. The company staged the commercial launch of its first product in Washington DC in September 2005.

USCOM’s business in the United States is managed by Mr Barry Zakar, Director of Operations, North America, a 30 year veteran of the American medical devices industry. Prior to joining USCOM, Mr Zakar was a senior executive for Edwards Life Sciences as a Director in Edwards’ Centre for Business Intelligence. Mr Zakar has extensive experience in the U.S. medical products industry, having held positions of Director of Marketing and Manager of Market Development for a number of leading medical devices companies.

Commenting on USCOM Inc today, Mr Zakar said, “USCOM is achieving a growing acceptance among clinicians as a valuable hemodynamics tool. USCOM Inc will empower the company to grow our North American presence and take full advantage of the great opportunities ahead. With our own corporate vehicle, USCOM is now able to participate more directly in the world’s biggest market.”

NEW EVIDENCE IN BREAST CANCER TREATMENT Cardiac monitoring mandatory for patient safety Important new application for USCOM

November 15th, 2006

USCOM Limited (ASX Code: UCM) today released the results of significant research into USCOM’s role in the management of breast cancer.

A paper presented this week at the German National Congress For Plastic and Reconstructive Surgery, demonstrated how USCOM can assist in the management of breast cancer patients undergoing chemotherapy.

The paper states, “Chemotherapy for metastatic breast cancer involves possible cardiotoxic agents. A thorough cardiac evaluation and monitoring during chemotherapy therefore is mandatory to increase patients’ safety. Immunotherapy with trastuzumab (Herceptin), a selective HER-2(ErbB2)-antibody, is approved in women with metastatic breast cancer and is associated with a certain degree of cardiotoxicity. The study sought to evaluate the immediate hemodynamic response to drugs as a possible marker of cardiotoxicity.”

The study, conducted at the Hannover University School of Medicine, involved 75 patients with HER-2-positive metastatic breast cancer who were continuously measured with the non-invasive USCOM monitor for stroke volume (SV), cardiac output (CO), cardiac index (CI), and systemic vascular resistance (SVR) before, during and after drug infusion.

The study concludes that using by USCOM, a different haemodynamic response to the infusion of different drugs is evident in women with metastatic breast cancer.

HER2-positive breast cancer refers to a type of breast cancer in which increased quantities of the HER2 (Human Epidermal growth factor Receptor 2) protein are present on the surface of the tumour cells. This is known as ’HER2 overexpression’. High levels of HER2 overexpression are present in a particularly aggressive form of breast cancer which responds poorly to chemotherapy.

Commenting on the announcement today, USCOM’s Chairman and Director of Clinical Science, Mr Rob Phillips MPhil(med), said, “This study confirms an important new application for USCOM in evaluating the cardiac effects of therapeutic drugs. Accurately measuring cardiac function is essential during any drug therapy and we have always believed that USCOM has an important role to play in monitoring cardiac function during drug treatments, whether that be for breast cancer, hypertension or heart failure. It is exciting to see this now being demonstrated in international science.”

Breast Cancer Abstract (.pdf 38kb)

Emergency Rescue Evidence Cover Story in Leading Journal

November 6th, 2006

“USCOM Feasible in Helicopter Rescue” “Rapid & Safe” “Therapy Verified immediately”

USCOM Limited (ASX Code: UCM) today announced the publication of significant scientific evidence supporting the role of the USCOM monitor in emergency retrieval.

A peer-reviewed paper demonstrating USCOM’s ability to manage patients during helicopter rescue appeared this week as a cover story in the prestigious Air Medical Journal, considered the premier provider of information for medical transport professionals. (The Air Medical Journal is the official journal of 5 leading medical transport associations in the United States.)

Commenting on the publication today, the Chief Executive of USCOM, Mr Gary Davey said “This paper has important implications for emergency medicine in general and trauma management in particular. It demonstrates how USCOM can play a leading role in the implementation of Early Goal Directed Therapy, not just at the hospital but at the earliest possible time in the management of the patient; right at the scene of the trauma. Having Dr Knobloch’s research published as the cover article in the Air Medical Journal is a milestone for USCOM.”

The 6-page article was authored by Dr Karsten Knobloch at the Hannover Medical School, where the USCOM monitor has been deployed at the scene of a wide variety of medical emergencies. The study was designed to determine whether USCOM could be used to measure haemodynamics, Cardiac Output (CO), Cardiac Index (CI) and Systemic Vascular Resistance (SVR), in flight with a Helicopter Emergency Medical Service (HEMS). Installed aboard Hannover’s Christoph 4 rescue helicopter, USCOM was used to measure 44 patients suffering a variety of medical emergencies, both at the site of the emergency and during flight back to hospital. The average time taken to record the USCOM measurements was 15 seconds. In addition to finding the USCOM method feasible, the study also found “the ultrasonic CO monitor is a rapid and safe measure and helps to start early goal-directed therapy as soon as the first professional medical contact.”

The study concludes, “The emergency physician gains additional crucial hemodynamic information rapidly to diagnose and treat patients adequately by directed administration of volume load and catecholamines at the scene and during flight conditions.”

Commenting on the publication today, the Chief Executive of USCOM, Mr Gary Davey said “This paper has important implications for emergency medicine in general and trauma management in particular. It demonstrates how USCOM can play a leading role in the implementation of Early Goal Directed Therapy, not just at the hospital but at the earliest possible time in the management of the patient; right at the scene of the trauma. Having Dr Knobloch’s research published as the cover article in the Air Medical Journal is a milestone for USCOM.”

Evidence Building: 23 Studies since July   “Momentum behind the USCOM method”   “Now at a critical point of adoption”

November 2nd, 2006

USCOM Limited (ASX Code: UCM) today released a summary of more than 20 new pieces of scientific evidence, supporting the role of the USCOM cardiac output monitor, across a wide range of applications.

Since July 1, 2006, medical professionals have presented 23 scientific papers, the busiest period of validation in the company’s history.

This signals an increasing momentum behind the USCOM non-invasive method in medical practice.

The research, conducted at centres of excellence in the USA, Europe, Asia and Australia, was conducted to assess the accuracy and reliability of the USCOM method, but also to identify USCOM’s role in clinical practice.

In all, 15 of the studies were conducted to test USCOM in the company’s primary target sectors; Paediatrics, Emergency and Intensive Care. In addition, important science has been presented in the lesser priority sectors of sports medicine and veterinary care.

The studies include validation research at some of Australia’s leading teaching hospitals, St Vincent’s, Royal Prince Alfred and Princes of Wales in Sydney, and the Prince Charles Hospital in Brisbane. And in the vital field of paediatrics, 3 important new studies were presented by Great Ormond Street Hospital in London, one of the world’s most respected children’s hospitals.

Summary of USCOM studies presented since July 1, 2006:

Paediatrics 3

Intensive Care 4

Emergency 3

Comparison with other methods 5

Elite Athletes 1

Vetinary 7

Total 23

(Copies of abstracts relating to each of the above studies are available on request or at the Validation section of the USCOM website, www.uscom.com.au)

The Chief Executive of USCOM, Mr Gary Davey said today “We can sense a steep escalation in the medical community’s acceptance of USCOM. The real significance of this research goes far beyond the issue of accuracy. The data reinforces our view that USCOM can improve outcomes and will reach adoption as a standard of care. This evidence is the engine that will drive USCOM to profitability. The science of USCOM has achieved critical mass just at a time when the evidence against the existing invasive methods is becoming overwhelming. We believe the company is now at a critical point in the process of adoption by the medical community.”

New Anaesthetics Studies in USA

November 1st, 2006

“Several advantages of USCOM device” “Real-Time, Beat-to-Beat Cost-effectiveness” “Excellent correlation without significant difference” “Accurate Alternative”

USCOM Limited (ASX Code: UCM) today announced the presentation of 2 new USCOM studies at the American Society of Anaesthetics (ASA) Annual Meeting in Chicago.

In one study, conducted at Keio University in Japan, approximately 230 measurements were taken from 40 patients to evaluate the accuracy of USCOM device compared with the invasive catheter method (CCO) in various situations in the hospital’s intensive care unit.

The study states, “The result indicates that the accuracy of USCOM was modest against CCO. However, taking into account that CCO overestimates cardiac output in most instances, the actual systemic bias may be less and clinically acceptable.”

The study concludes, “Several advantages of USCOM device, such as real-time, beat-to-beat assessment and cost-effectiveness prompt further clinical application.” Keio ASA Abstract (.pdf 39kb)

A second study, conducted at the University of Arizona Medical Centre, compared USCOM to 5 alternative methods of measuring cardiac output (CO), including catheters, ultrasound, and artificial hearts.

The paper, titled “USCOM-Non Invasive Doppler – Are Cardiac Output Measurements Accurate in Both Infants and Adults?” was co-authored by Dr Peter Lichtenthal and Dr Jack Copeland from Arizona’s internationally recognized cardiac surgery team. After 560 paired measurements, the study found a percentage error between measures of 0.1 %. “There was excellent correlation of CO without significant difference (r=0.996, p<0.005).”

The study concludes, “Non-invasive USCOM measurements of CO compare favorably to current clinical measures in children and adults across a wide range of sizes and COs. These data confirm that the non-invasive USCOM is an accurate alternative to current methods for determining CO.”

Lichtenthal ASA Abstract (.pdf 36kb)

The ASA annual meeting is considered the world’s largest and most important gathering of anaesthetists.

Three new USCOM Emergency Studies

October 26th, 2006

“A major advance in patient assessment” “Highly accurate yet entirely non-invasive” “Solution to the ED dilemma” “Great value to the ED physician”

USCOM Limited (ASX Code: UCM) today announced the presentation of 3 important scientific studies supporting the role of USCOM in emergency medical care.

The studies were presented this week at the Emergency Medicine Scientific Symposium being held in Hong Kong.

In one study. clinicians assessed the reproducibility of the USCOM cardiac output method among operators in an Accident and Emergency department after standard USCOM training.

The study, conducted by Dr Michael Tam at Hong Kong’s Prince of Wales Hospital, involved blinded measurements from 119 patients. The study found the differences between operators “were very small and therefore unlikely to result in differences in clinical decision-making.”

The study states, “Early recognition and treatment of shock has been shown to improve patient outcome and survival dramatically. Physical examination and conventional vital signs are known to be inaccurate. Central haemodynamic indices (e.g. cardiac output) are much more sensitive in this respect. Pulmonary catheterization and thermodilution is impractical in the emergency department (ED). By the time the patient reaches the intensive care unit (ICU), the ’golden hour’ to treat shock with the best possible outcome has passed.”

“Non-invasive cardiac output measurement using portable Ultrasonic Cardiac Output Monitor (USCOM) is the solution to the above dilemma.”

The study concludes, “USCOM has a high level of inter-operator agreement despite its operator-dependent nature, and would be of great value to the ED physician for the early recognition of shock and for monitoring response to resuscitation.”

Prince of Wales, Hong Kong Abstract (.pdf 27kb)

A second study, submitted by Dr Brendan Smith from the Broken Hill Base Hospital in Australia, included data from more than 100 children aged between 1 and 16 years to demonstrate the need for change in the way children are managed in an emergency department setting. The study highlighted the lack of reliable information about septic shock in children and warned of the risks involved in applying assumptions about adults in the management of sick children.

The study states, “The advent of the highly accurate yet entirely non-invasive ultrasonic cardiac output monitor (USCOM) permits the rapid (less than 5 minutes) determination of CO, CI, SV, SVR and DO2. The data can then be used to institute early goal directed therapy and for regular monitoring to ensure that haemodynamics are optimised.”

“We suggest that in the case of the shocked child, extrapolation for haemodynamic values derived from adult investigations are largely inappropriate and potentially dangerous, with serious risk of inadequate treatment of the child.”

Broken Hill Abstract (pdf 27kb)

The third paper, based on a pilot study conducted at the Prince of Wales Hospital in Hong Kong, used USCOM to assess the haemodynamics of 40 patients with cardiovascular emergencies, as a means of establishing a patient prognosis.

The study states, “USCOM represents a major advance in patient assessment in the emergency department. It enables the emergency physician to gain essential information on the central haemodynamics of patients requiring resuscitation. Clinical applications of USCOM include early shock recognition, differential diagnosis of shock, monitoring therapy, goal-directed resuscitation and transcutaneous pacing.”

The study identified a significant connection between patients with a lower initial Cardiac Index, as measured by USCOM, and adverse outcomes during hospitalisation.

Commenting on the 3 new studies today, the Chief Executive of USCOM, Mr Gary Davey said, “Each of these new papers represent a significant shift in the thinking about Emergency Department management. They demonstrate how USCOM can be used safely and reliably among both adults and children to improve patient outcomes in the ED. It is especially significant to see clinicians now recognising USCOM’s role in the implementation of Early Goal Directed Therapy, establishing an accurate prognosis for the patient immediately upon admission.”

“We have no doubt that USCOM will become a standard of practice in emergency care.”

Prince Of Wales Hong Kong, Emergency Abstract (.pdf 27kb)

3 New Studies at ICU Congress  Highly Correlated with Fick & PAC  Exam time reduced to 5 minutes  Short Learning Curve  “Reliable & Accurate”

October 16th, 2006

USCOM Limited (ASX Code: UCM) today announced the presentation of 3 new USCOM studies, at Australia’s biggest national conference on Intensive Care.

The Australian and New Zealand Intensive Care Society’s Annual Scientific Meeting on was held in Hobart from October 12 to 15.

The 3 studies were conducted at hospitals in Sydney and Brisbane to determine the accuracy and usability of the USCOM non-invasive cardiac output monitor in an intensive care setting.

Prince Charles Hospital, Brisbane:

One of the studies, conducted at Prince Charles Hospital in Queensland tested the ability of an ICU nurse, with no previous experience with ultrasound, to reliably measuring Cardiac Output (CO) with the USCOM device in heart failure patients. The study also compared USCOM with 2 established methods, PAC thermodilution and the Fick method, and reported that USCOM highly correlated with the 2 established and invasive methods.

The study, authored by Amanda Corley, from Prince Charles’ Critical Care Research Group, concluded: “USCOM has been found to be reliable and accurate in measuring CO. The learning curve for successful usage of USCOM by an ICU nurse is satisfactorily short which suggests USCOM could be used by appropriately trained nursing staff to non-invasively determine CO.”

Importantly, the study also illustrated the improvement in results as the user gains experience with the USCOM device. The study found that with experience the time needed to acquire optimal USCOM signals “reduced from 25 minutes to 5 minutes despite the technically difficult study population.”

Commenting on the Prince Charles research today, the Chief Executive of USCOM, Mr Gary Davey said, “We have always believed that the change in practise that USCOM offers will be driven by nurses. Our technology was designed for use by nursing staff and we are committed to advancing this important process of change and the associated cost benefits this will bring to health care. Amanda Corley’s work is a significant milestone for USCOM, proving that nurses can reliably measure Cardiac Output, quickly, accurately and most importantly with complete safety.”

Prince Charles Abstract (.pdf 22kb)

Prince of Wales Hospital, Sydney:

A second study, conducted at the Prince of Wales Hospital in Sydney, tested the ability of novice users to effectively use USCOM in Emergency, High Dependency and Intensive Care departments. The study found some inter-operator variability in signal acquisition. However, the study conducted by Dr Liz Steel, concluded, “ the novice user can obtain technically acceptable determinations and reliably determine low or high CO”.

St Vincent‘s Hospital, Sydney:

The third study was conducted by Dr Janet Chan at St Vincent’s Hospital in Sydney, where an early model of the USCOM monitor was compared with the PAC thermodilution method among the technically challenging group of post cardiac surgery patients. The study concluded, “Given accepted inherent inaccuracies of continuous cardiac output assessment, further investigation is required to validate the suitability of the USCOM device in this patient population.”

USCOM sales and marketing staff are attending the Australian and New Zealand Intensive Care Society’s Annual Scientific Meeting and demonstrating the non-invasive USCOM device to Australasian clinicians as an alternative to current intensive care methods for measuring cardiac haemodynamics.

USCOM Role for Sick Children

October 9th, 2006

  New study presented at Europaediatrics 2006   Managing Renal Therapy    Excellent example of evidence for change

USCOM Limited (ASX Code: UCM) today announced the presentation of a new scientific study, providing further evidence for USCOM’s role in the management of sick children.

The study, conducted at the prestigious Great Ormond Street Hospital in London was presented at Europaediatrics 2006, Europe’s largest scientific conference for the clinical management of children, being held in Barcelona Spain. The paper titled, “Effects of Initiation Of Continuous Renal Replacement Therapy On Haemodynamics in Critically Ill Children” was presented by Dr Joe Brierley from Great Ormond Street’s Paediatrics Intensive Care Unit.

In his study, Dr Brierley used USCOM to measure cardiac output and other haemodynamic variables among children undergoing CVVH, an artificial kidney filter method for removing waste products and excess water from the body. By providing direct physiological measurements, USCOM played a role in defining the appropriate therapy.

Dr Brierley’s paper states “Haemodynamic instability is often met by countering ’filter-related decreased systemic vascular resistance (SVR)’ with vasoconstrictors. Newer non-invasive haemodynamic techniques may allow more physiological management.”

And the paper concluded, “Initiating CVVH in critically ill children induces hypovolemia leading to a systemic cardiovascular response of vasoconstriction and overall decrease in cardiac output. This may represent haemodilution with lowering of effective inotropic concentration through increased volume of distribution, or there may be a direct negative inotropic effect of initiating CVVH. Physiological based therapy would consist of increasing inotropes, rather than vasoconstrictors”.

Commenting on the study today, the Chief executive of USCOM, Mr Gary Davey said, “Paediatrics is a primary focus for USCOM and we are excited that centres of excellent such as Great Ormond Street Hospital are demonstrating the importance of measuring cardiac output in sick children. This study is an excellent example of how USCOM may fundamentally change existing practice, methods and management protocols.”

Cardiac Surgery Abstract(.pdf 55kb)

New Cardiac evidence for USCOM  Accuracy shown against 5 methods  Study shows excellent correlation  Most significant evidence to date  25 New Studies to be released

September 25th, 2006

USCOM Limited (ASX Code: UCM) today announced the presentation of an important new scientific study, validating the company‘s cardiac output monitor against 5 different alternative methods. This is the first in a series of 25 new studies the company expects to be released over the coming months.

The study, conducted at the University of Arizona Medical Centre in Tucson was presented today at the European Society of Intensive Care Medicine Conference in Barcelona, Spain.

The study, co-authored by Dr Jack Copeland, one of the world’s leading heart surgeons, assessed the accuracy of the non-invasive USCOM method of measuring cardiac output, compared with:

Across more than 500 measures among patients aged from 3 months to 82 years, there was virtually no difference between the USCOM measurements and the mean of the 5 alternatives.

The paper presented today states, “The potential for a single CO measurement method to be used contiguously across a range of ages and CO values has the potential to significantly change clinical practice, particularly if the method is non-invasive so that repeated measurements can be made without risk cost.”

The study concludes, “USCOM measurements of CO compared favourably to current clinical measures across a range of COs in children and adults. USCOM is a single, non-invasive alternative to manycurrently used methods in the cardiac surgical environment. A contiguous method of CO measurement mayimprove clinical practice.”

Commenting on the study today, the Chief executive of USCOM, Mr Gary Davey said, “In many ways, this may prove to be the most significant USCOM validation to date. USCOM has now been proven to be accurate when compared to virtually every available method of cardiac output measurement. We are delighted to have this evidence from Dr Copeland’s Tucson team, one of the most respected cardiac surgery units in the world.”

Europaediatrics Abstract (pdf 61kb)

USCOM RELEASES 06 ANNUAL REPORT

September 22nd, 2006

USCOM Limited (ASX Code: UCM) today released its annual report for the year ending June 30, 2006.

In FY ’06, the company achieved revenue from sales of $1.12 million a year-on-year increase of 133%, having secured the commitments for the purchase or rental of 67 USCOM monitors. With net cash outflow for the year of $3.3 million, USCOM Ltd had $7.2 million cash in hand at the end of June. The company has continued to carefully manage its cash resources, while at the same time, accelerating sales and marketing activity in all our priority territories.

In his letter to shareholders, the Chairman of USCOM, Mr Rob Phillips said, “We are proud of the important milestones the company has achieved in the two-and-a-half years since listing on the Australian Stock Exchange. We have completed the development of a practise-changing medical device, secured regulatory approvals worldwide, built a strong scientific case for our product, created an international sales and distribution network and laid the groundwork for a highly profitable business. By any measure, and especially against historical comparisons in the life sciences sector, this represents very rapid progress.”

FINANCIAL HIGHLIGHTS

Total Revenue – $1,716,529
Total Costs – $5,158,809
Profit / (Loss) – ($3,374,210)
Sales Revenue – $1,119,622
Net operating cash outflow – $3,187,788
Cash in hand at 30 June – $7,222,322

USCOM Annual Report 2006 (.pdf 1945kb)

Changes to USCOM Board

September 8th, 2006

USCOM Limited (ASX Code: UCM) today announced the retirement of 2 of the company’s founding directors.

Mr Luke Fay and Dr Fred Berry have served as directors and members of board sub-committees since 2001.

The Chairman of USCOM, Mr Rob Phillips said, “USCOM has been a challenging and pioneering project. It would not have been possible without the knowledge and experience of our founding directors. Dr Berry brought to the company a lifetime of practical knowledge of medical science and clinical practice. While Mr Fay was instrumental in guiding the formative stages of both the company and the USCOM device. We sincerely thank them for their outstanding contributions.”

The company is currently in discussion with a number of candidates for independent non-executive directorships.

USCOM PROVEN IN NEW STUDY

September 7th, 2006

“Excellent Agreement” with catheter method  “A simple tool that is easy to use”  “5 articles & Journal editorial challenge PAC”

USCOM Limited (ASX Code: UCM) today announced the publication of an important new peer-reviewed study, confirming the accuracy of the USCOM non-invasive cardiac output monitor.

The study, published in the Journal of Cardiothoracic and Vascular Anesthesia, was based on 50 patients after coronary artery bypass surgery, comparing USCOM to the Bolus Thermodilution catheter method for measuring Cardiac Output (CO), Stroke Volume (SV) and Cardiac Index (CI). The study found “excellent agreement” between the USCOM and the catheter methods for each of the three parameters.

The study was conducted by Dr Rajesh Chand at the Department of Anesthesiology and Critical Care, at the Escorts Heart Institute and Research Centre, New Delhi, India. The paper concludes, “The acceptability of any new technique depends on reproducibility, ease of use, lack of operator bias, and cost. USCOM is a simple tool that is easy to use in the postoperative recovery period and in preoperative patients”.

“There is minimal observer bias and no recurring cost after the initial investment in hardware (monitor and probe). In conclusion, USCOM appears to be useful for reliably determining noninvasive CO estimations and trending in postoperative cardiac surgery patients.”

The USCOM paper was accompanied by 5 articles challenging the role of the catheter method and an editorial by Professor Jeffery Vender from Northwestern University, titled, “Pulmonary Artery Catheter Utilization: The Use, Misuse, or Abuse”

The editorial stated, “This past year, several more articles have been published reconfirming the previously reported lack of outcome benefit from PAC use. In this issue of the Journal, 5 more articles appear addressing the use of the PAC and its impact on patient outcome. These articles suggest that PAC use may result in patient harm. The mantra of negativism has been heard and it is getting louder; but before abandoning the PAC (or as some have referred to it, the “Swan Gone(z)”catheter), the issues raised in the literature, as well as the proposed alternatives for patient management, must be reassessed.”

“…this author must concur and support the opinion that the routine use of PACs in low-risk patients is probably unwarranted. No technology or diagnostic modality should be employed inappropriately, excessively, indiscriminately, and without a demonstration of benefit. It is this author’s contention that clinicians’ greatest issues are not with the PAC, but with their understanding and utilization of this technology.”

Commenting on the publication, the Chief Executive of USCOM, Mr Gary Davey said, “The journal articles and editorial add further weight to the case against the invasive catheter method and provide powerful evidence in support of a non-invasive and accurate alternative such as USCOM.”

USCOM Sells Coefficient Systems stake

August 24th, 2006

USCOM Limited (ASX Code: UCM) today announced the sale of its 10% equity holding in medical equipment distributor, Coefficient Systems Pty Ltd, realising a substantial gain on this investment.

The final sale price is subject to an audit of Coefficient Systems’ 2006 financial year results as well as a possible premium at the end of FY 07. USCOM anticipates a net gain of between $400,000 and $500,000 on the transaction.

An initial payment of $175,887, being the first of 3 distributions, will be made at settlement. The Coefficient Systems investment is recognised on the USCOM balance sheet at an asset value of $100,030.

USCOM acquired its stake in Coefficient Systems Pty Ltd in 2002 when the company was appointed as USCOM’s exclusive marketing & distribution agent for Australasia. In March 2005, USCOM amended its agreement with Coefficient for the appointment of its own direct sales force for Australia. Coefficient Systems continues to represent USCOM in certain markets in South East Asia and the Middle East.

Coefficient Systems is being acquired by MMT Healthcare Pty Limited, now trading as Lifehealthcare, a leading Australian medical equipment and healthcare services business.

Three New USCOM Studies at Cardiac Conference

August 5th, 2006

USCOM Limited (ASX Code: UCM) today announced the presentation of three scientific studies at a major Cardiac conference in Australia, with significant implications for patient management.

The presentations were made at the 54th Annual Scientific Meeting of the Cardiac Society of Australia & New Zealand, being held in Canberra, August 4-7.

One of the studies used the USCOM non-invasive cardiac output monitor to assess a group of 26 elite athletes before and after exercise. The study, conducted by Dr Karsten Knobloch at Hannover University Hospital in Germany, assessed cardiovascular performance from rest up to 72% maximum oxygen consumption, measuring USCOM and blood pressure.

The study found the pressure measurements delivered poor correlation across 77 paired measurements.

The study concluded, “Arterial pressures showed poor correlation with CO (Cardiac Output) and SVR (Systemic Vascular Resistance) at baseline and during increased oxygen consumption, suggesting that arterial pulse pressure measurement is a poor physiologic analogue of either cardiac or vascular function.”

These results have important ramifications for the management of hypertension and sepsis.

Dr Knobloch Abstract( .pdf 30kb)

In another presentation, data was presented to show USCOM to be a viable alternative to traditional echocardiography in the assessment of pre-term neonates. The study, conducted at Royal Prince Alfred Hospital in Sydney concluded, “These results suggest that USCOM is as accurate for measurement of neonatal CO as conventional echo, and may make a cost-effective contribution to neonatal haemodynamic management.”

RPA Neonates Abstract( .pdf 21kb)

And a third study, conducted at the prestigious Howard Florey Institute in Melbourne, compared USCOM with the gold standard Flow-Probe method as well as the industry standard Pulmonary Artery Catheter (PAC) in animals. The study found that Flow-Probes and USCOM showed good correlation (r=0.745), while Flow-Probes and PAC poorly correlated (r=0.323).

Sheep Abstract( .pdf 21kb)

Two USCOM Units For Sydney Children’s Hospital

July 13th, 2006

USCOM Limited (ASX Code: UCM) today announced the installation of 2 USCOM cardiac output monitors at the prestigious Sydney Children’s Hospital.

The 2 USCOM machines have been deployed at the hospital’s Intensive Care and Anaesthetics departments, where clinicians can now reliably measure the haemodynamics of young children and babies with USCOM’s completely non-invasive method.

One of the units was ordered by the Intensive Care Department while the second was made available through a charitable donation by Mr Brent Potts of Southern Cross Equities.

The Sydney Children’s installations are strategically important for USCOM because the hospital will serve as a world class reference site, advancing USCOM’s reputation among paediatrics clinicians.

Commenting on the latest USCOM orders, the company’s Chief Executive, Mr Gary Davey said, “We will be working very closely with Sydney Children’s in the development of USCOM’s role in the care of young children and babies. This is an internationally recognised centre of excellence and we are proud to have the hospital as an important new customer.”

About Sydney Children’s Hospital Sydney Children’s is part the Randwick Campus adjacent to the Prince of Wales Hospital and the Royal Hospital for Women, together, the largest complex of teaching hospitals in Australia. The hospital admits 14,000 children per year and treats 200,000 through emergency, outpatient and outreach services. Sydney Children’s is the site of two extraordinary recent cases, including that of 5-year-old Sophie Delezio, who was critically injured when hit by a car, just 3 years after suffering terrible burns in another freak motor accident The hospital also recently completed successful “hole-in-the-heart” surgery on a 2-month old baby girl from East Timor.

NEW TESTIMONIAL FOR USCOM

July 3rd, 2006

USCOM Limited (ASX Code: UCM) today released a new testimonial from an internationally recognised clinician, describing the USCOM monitor as “the only truly accurate non-invasive cardiac output system”.

The statement was made by Dr Peter Lichtenthal, Associate Professor and Director of Cardiovascular Anesthesia, at the University of Arizona College of Medicine in an interview in Tucson, Arizona.

Dr Lichtenthal heads up the practice leading anaesthetics team at the University of Arizona Medical Centre, the home of ground-breaking work in cardiac surgery and transplantation. Dr Lichtenthal and his colleagues have been using the USCOM non-invasive cardiac output monitor in daily clinical practice for almost 2 years across a wide range of applications.

In the interview, Dr Lichtenthal said his team found the USCOM system valuable because of its mobility, because of its easy accessibility, and its ability to provide answers whenever needed, 24 hours a day.

He said he found USCOM very valuable in the underserved pediatric intensive care population where traditionally these patients could not be monitored to get cardiac output 24 hours a day. “Whenever we want we can get an output and we can follow a baby’s success and we find that very, very helpful. What I’m interested in, and what, as a group, our cardiac group is interested in is getting a treatment modality and cardiac output is a treatment modality for pediatric patients.”

Dr Lichtenthal said there was also an important role for USCOM in managing heart failure patients. “In heart failure, we find that non invasively, safely, without any source of infection because of invasion, we can get a cardiac output and follow their progress, or lack of progress, towards a bridge to transplant or a device, whatever.”

“I think that the best part of USCOM is its portability. We call it “CCO on the go”, wherever you need it, you can get it.”

“We’ve used it in ambulances, we’ve used it in people that didn’t have instrumentation that we went to get. We’ve used it for recently arrived people before we could instrument them. But it’s readily available if you need it in the emergency room, if you need it up in the unit, if you need it in the operating room, you can just bring the machine everywhere very, very easily.”

When asked how the USCOM device compared with other cardiac output methods, Dr Lichtenthal said, “USCOM is the only truly accurate non-invasive system.”

KEY SALES APPOINTMENT

June 8th, 2006

USCOM Limited (ASX Code: UCM) announced today the appointment of Mr Len Bevis, a 30-year-veteran of the medical devices business as USCOM’s National Sales Manager for the Australasian region.

Mr Bevis brings to USCOM a wealth of experience in the Australian medical industry, with exposure to a diverse range of consumables, devices and equipment across a broad customer base. He has an extensive knowledge of and contacts in the hospital system, both public & private, having led a number of sales teams as a National Sales Manager and Director of Sales and Marketing.

Mr Bevis, who takes up his new role on June 13, will report to the Chief Operating Officer of USCOM, Mr Paul Butler. Mr Bevis’ duties will include the management and expansion of USCOM’s direct sales team in Australia.

The appointment of Mr Bevis is a key part of a strategic expansion of the sales management team at USCOM. In April 2006, USCOM announced the appointment of Mr Albert Sorrell to assist in a restructuring of USCOM’s sales and marketing organisation.

Commenting on the appointment today, the Chief Executive of USCOM, Mr Gary Davey said, “This is an important step in the development of our company. Len Bevis provides the depth of experience we need to take the company to the next level in sales and marketing. The Australian sales team has made tremendous progress in the 12 months since its inception and we are delighted to have someone of the caliber of Len Bevis to take on the leadership of this team.”

USCOM CITED IN BRITISH JOURNAL

May 18th, 2006

USCOM Limited (ASX Code: UCM) today announced the publication of an endorsement for USCOM’s non-invasive heart monitor system in the latest edition of the British Journal of Hospital Medicine.

Clinicians from 2 hospitals in the South of England described the role of the USCOM cardiac output monitor in the management of fluid levels in patients in surgery and post-operative critical care.

Comparing USCOM with other invasive methods, the 2 clinicians said,

“We feel that a more promising alternative on the horizon is the USCOM non-invasive cardiac output monitor.”

In describing other methods, the article states, “The pulse contour analysis and SPV (systolic pressure variation) require the presence of an arterial line and the oesophageal Doppler study at present can only be done in sedated patients. Most surgical wards are reluctant to take patients with arterial lines in situ and hence these techniques are usually limited to the minority of post-surgical patients who are transferred to the intensive care unit or high dependency unit.”

The article refers to a previous study which had found the USCOM method to be “accurate, rapid, safe, well-tolerated, non-invasive and cost-effective.” It also referenced other studies which found USCOM to be useful in the emergency department and air rescue service.

The 2 authors are Dr A. Sange, Senior House Officer, Critical Care Directorate, Darent Valley Hospital in Dartford and Dr M. Sange, Specialist Registrar, Department of Anaesthetics, Medway Maritime Hospital, Gillingham.

A related article in the journal further emphasised the importance of fluids management in critical care. Dr Kate Tatham, from the Critical Care Unit at London’s Royal Marsden Hospital referred to scientific studies demonstrating that by optimising circulatory status clinicians can reduce both the length of intensive care stay and over-all morbidity. Dr Katham opened the article by saying,

“About 95% of bleeps I receive while on call concern fluid balance.”

The article concludes, “Paying a little attention to fluid balance can significantly change a patient’s outcome.”

British Journal of Hospital Medicine article (339kb)

THE CASE FOR USCOM Editorial Letter, Emergency Medicine Australasia

May 4th, 2006

USCOM Limited (ASX Code: UCM) today announced the publication of a significant article in the latest edition of Emergency Medicine Australasia (EMA), supporting the use of USCOM’s non-invasive cardiac output technology in Emergency Care.

The article puts the case that there is now an overwhelming case for non-invasive haemodynamics in the emergency setting.

“In neonates and children, the case is even more compelling with a reluctance to tolerate the risks of invasive Cardiac Output (CO) measurements despite proven haemodynamic optimisation benefits, particularly in septic shock.”, the article states.

The article, produced in response to a recent EMA editorial, was co-authored by Dr Bob Bilkovski, Associate Research Director at the Henry Ford Hospital, Detroit, Dr Joe Brierly from the Great Ormond Street Hospital for Children in London, Dr Fred Berry, an anaesthetist and USCOM director and Mr Rob Phillips, USCOM’s Director of Clinical Science. The following are extracts from the co-authored letter:

“USCOM is a sophisticated CW Doppler device for simple and accurate SV (Stroke Volume) and CO measurement displayed to enhance understanding of trend haemodynamics. It has been validated against flow probes in animals, against echocardiography, and against thermodilation in CO from 0.12 to 17 Litres Per Minute2.

The Editorial in calling for more outcomes evidence in support of non-invasive devices fails to consider that changing SV and CO is so fundamental and intuitive to haemodynamic management and with such obvious benefit, that it would be unethical to randomise an untreated arm for any outcome study. That optimizing haemodynamics improves outcomes has been proven in emergency applications for treatment of sepsis3, in the presurgical, intraoperative and post-surgical environments4, and in electrophysiology5, with reported decreases in mortality and hospitalization costs of 30-40%. Such substantial benefits surely warrant an energetic clinical focus on haemodynamics and early optimisation?

Large urban EDs in the USA, including the Henry Ford Hospital in Detroit, have adopted early goal-directed therapy (EGDT) as a standard of care because the intervention is patient-focused – improving patient outcomes and reducing hospital resource utilization. The Editorial‘s acceptance that current practice remains focused on invasive methods despite abundant negative evidence regarding efficacy, safety and ease of use6 has implications beyond medical care and raises important medico-legal questions.

If evidence is a concern, then it is invasive methods that require review.

While the Editorial correctly states that SV is not DO2, optimizing SV is the therapeutic approach for increasing DO2, so SV is the appropriate entity to monitor during therapy. In fact, the ScvO2catheter was validated against SV.

While invasive measures may take significant time, often exceeding “the golden hour” for optimizing mortality and morbidity benefit, USCOM takes less than 30 seconds per Stroke Volume measure.

We would contend that the time challenges imposed upon emergency physicians worldwide are the predominant rate-limiting step for the widespread implementation of EGDT. The Editorial recommends the use of echocardiography in cardiogenic shock, and echo is certainly important for diagnosis. However, echocardiography provides a single point snapshot of morphology and haemodynamics, and is not a cost-effective approach to serial haemodynamics. Additionally, USCOM is easier and quicker to use, may be more sensitive than echocardiography, and can be applied in remote centres with minimum training.

While identifying the costs of new technology, USCOM is approximately 20% of the capital cost of ultrasound, has no maintenance cost, and, unlike invasive measures, has no incremental cost per measure or associated morbidity and mortality cost. Clearly, the most objective benefit in use of non-invasive CO technology is the cost saving associated with reduced intensive-care-unit stays and decreased hospital resource utilization.

Clearly evidence suggests a non-invasive method providing rapid, accurate and real-time rate and SV measures provides opportunities to improve patient care in the ED, and should be received with enthusiasm and not negativity.”

To cite this article: Phillips, Rob; Bilkovski, Robert; Brierley, Joe and Berry, Fred (2006) Making the case for USCOM. Emergency Medicine Australasia 18 (2), 205-206. doi: 10.1111/ j.1742-6723.2006.00843.x.

References

  1. 1. Bernard S. The patient with shock: is there any role for the noninvasive monitoring of cardiac output? Emerg. Med. Australas. 2005; 17: 189-90.
  2. 2. Knobloch K, Lichtenberg A, Winterhalter M, Rossner D, Pichlmaier M, Phillips R. Non-invasive cardiac output determination by two-dimensional independent Doppler during and after cardiac surgery. Ann. Thorac. Surg. 2005; 81: 1479-81.
  3. 3. Rivers E, Nguyen B, Havstad S et al. Early goal directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001; 345: 1368-77.
  4. 4. Sinclair S, James S, Singer M. Intra-operative intravascular Volume optimization and length of hospital stay after repair of proximal femoral fracture: randomized controlled trial. Br. Med.J. 1997; 315: 909-12.
  5. 5. Cleland JGF, Dawbert JC, Erdmann E et al. The effect of cardiac resynchronyization on morbidity and mortality in heart failure. N. Engl. J. Med. 2005; 352: 1539-49.
  6. 6. Shah MR, Hasselblad V, Stevenson LW et al. Impacts of the pulmonary artery catheter in critically ill patients: Meta-analysis of randomised trials. JAMA 2005; 294: 1634-70.

CHILDREN’S SITE ORDERS 2 UNITS Emergency & Sports Medicine Applications

April 20th, 2006

USCOM Limited (ASX Code: UCM) today announced the installation of two non-invasive cardiac output monitors at the prestigious Children’s Hospital at Westmead in Sydney.

The USCOM monitor has been ordered by Westmead’s Accident & Emergency Department as well as the Children‘s Hospital Institute of Sports Medicine (CHISM).

The USCOM system will be used in clinical practice in the Emergency Department of The Children’s Hospital at Westmead and will be part of a research project into its use in acutely unwell children. This installation has been made possible by a generous donation from the Day of Difference Foundation.

Commenting on the Westmead installations, the Chief Executive of USCOM, Mr Gary Davey said, “It is a great step forward for USCOM to be adopted at a prestigious site such as the Children’s Hospital at Westmead, a centre of excellence in paediatrics, neonatology and the retrieval of sick and injured children. We will be working very closely with Westmead in the development of USCOM’s role in a wide range of clinical applications. At the same time, the company is delighted to be now a part of the research programme at CHISM, a recognised leader in the field of sports medicine for children.”

About Westmead The Children’s Hospital at Westmead is a teaching hospital of the University of Sydney, with a bed capacity of 339 and annual presentations to the Emergency Department of 42,000.patients. About CHISMCHISM was established in 1995 within the framework of The Children‘s Hospital at Westmead. The mission of CHISM is to provide the highest quality services in paediatric sports medicine and exercise science through clinical care, research, policy development, promoting good practice, education and training, consulting and working with key community stakeholders and engaging in advocacy issues on behalf of children and youth.

The two Westmead units bring to 8 the number of paediatrics installations for USCOM in the past 3 months.

On March 8, the company announced two important new paediatrics sites in Asia, the Shenzhen Children’s Hospital in Southern China and the Saitama Paediatrics Hospital in Tokyo. USCOM machines have also been installed at the Neonatology department of the Mercy Hospital in Melbourne, at two important paediatrics centres in the United States and at the Duchess of Kent Children’s Hospital in Hong Kong, a major regional referral centre for paediatrics.

USCOM’s role in Paediatrics

New research on USCOM’s role in paediatrics was recently presented at the 26th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium, attended by almost 5,000 clinicians from around the world. The study, conducted at Royal Prince Alfred Hospital in Sydney, supported USCOM’s role in the management of sick children. The study was designed to test the accuracy of the USCOM method of measuring blood flow through the hearts of pre-term neonates, ranging in size from 3.1 kilograms down to just 390 grams, with cardiac outputs from 0.12 to 1.61 Litres Per Minute.

Using the established Echocardiographic method (2D imaging and Doppler) for comparison, the study found no significant difference between the Echo and USCOM measurements, with a mean error between measurements of -3.7%. Importantly, the study also concluded, “USCOM is an accurate method for measurement of neonatal cardiac output and may be more sensitive than conventional echo for the detection of haemodynamic change. USCOM is a simple, cost-effective alternative for neonatal haemodynamic management”.

The importance of the company’s focus on the paediatrics sector has also been highlighted by the recent release of 2 significant scientific studies from the Vanderbilt Children’s Hospital in the U.S. and from the Great Ormond Street Hospital in London. The Vanderbilt study concluded “With low intra-user variability and an average measurement time of less than 2 minutes, the USCOM device proves to be a practical method of assessing cardiac status in a pediatric critical care setting.“

SALES UPDATE - 20 UNITS SHIPPED IN Q3, 50 UNITS YEAR-TO-DATE

April 11th, 2006

USCOM Limited (ASX Code: UCM) today announced it had closed its third quarter of the current financial year with 20 new orders, resulting in a year-to-date cumulative total of 50 USCOM devices.

The majority of the 20 new systems were purchased outright, but for the first time, a small number of customers took up USCOM’s recently launched programme for lease or rental, with purchase options, depending on the customer’s funding cycle.

Commenting today, the Chief Executive of USCOM, Mr Gary Davey said, “This is an outstanding result. The January to March quarter is traditionally the slowest period of the year as markets wind back up after the New Year. But the quarter just ended will be noted as an important turning point for USCOM.”

Mr Davey added, “We anticipate a big performance from all our markets in the final quarter, especially in North America. The US constitutes the single biggest component of our fourth quarter target and will be the most important variable in the final result. Our key US distribution partner, TriAnim Inc, has been active in the market with the USCOM product since January and reports excellent feedback from prospective customers. We believe our investment in marketing in the U.S. will convert to a successful close to the year.”

USCOM is especially pleased by the performance of its Australian direct sales force, recruited in mid 2005, which delivered 10 unit orders in Q3. Important sales were achieved at key reference sites in the capital cities, in regional centres and in one of the company’s priority market segments, paediatrics.

GROWTH IN REGIONAL SALES - 5 NEW ORDERS, NOW 11 USCOM SITES

April 6th, 2006

USCOM Limited (ASX Code: UCM) today announced further progress in establishing the company’s technology as a standard of care in rural Australia, with the sale of a further 5 USCOM machines at regional medical centres.

This brings to 11 the number of USCOM machines in clinical practice at hospitals and general practice clinics in regional Australia.

Among the most significant new sites is the 103-bed Grafton Base Hospital in Northern New South Wales. The Grafton installation was made possible by a charitable fund-raising effort led by Grafton ambulance officer, Rob Brown who raised funds from a charitable walk along the Kokoda Trail in Papua New Guinea. The effort was supported by adventure travel group, Our Spirit.

Commenting on the Grafton sale, the Chief Executive of USCOM, Mr Gary Davey said, “In recent weeks, we have confirmed sales in a further 5 regional sites and we anticipate significant growth in this sector through 2006. With intense pressure on equipment, budgets and staff, regional health care providers are in need of efficient and cost-effective methods and USCOM fits that bill perfectly. This is especially true when the USCOM technology is used to reduce the number of patients who need to be transported to capital city hospitals. This is an exciting sector for the company. In the case of Grafton, the company has been touched by the commitment of doctors and the local community in raising funds for this equipment. We are proud to be working with them.”

In addition to the Grafton order, the company today also confirmed the sale of an USCOM monitor to a leading General Practitioner in Broken Hill, New South Wales. Broken Hill has been an important out-post for USCOM, with Dr Brendan Smith conducting pioneering work with the USCOM machine at the Broken Hill Base Hospital, USCOM’s first Australian hospital customer.

Also in regional New South Wales, USCOM has been adopted by a leading clinician at Armidale and in Queensland, the company this week confirmed the sale of an USCOM device to the Emergency Department of Beaudesert Hospital.

The following are the regional sites where USCOM has been adopted:

EXEC TEAM EXPANSION

April 5th, 2006

USCOM Limited (ASX Code: UCM) today announced changes to the management structure of the company, further enhancing USCOM’s capacity in global sales and marketing.

The company has appointed Mr Albert Sorrell, a veteran of the Australian medical devices industry to assist in a restructuring of USCOM’s sales and marketing organisation. This includes the recruitment of a new senior executive with responsibility for global sales. Mr Paul Butler, previously USCOM’s Sydney-based General Manager, is to take the role of Chief Operating Officer with immediate effect.

Commenting on the changes today, the Chairman of USCOM, Mr Rob Phillips said, “The company has now reached an important point in its evolution from a start-up. It is time to take a more aggressive position in the development of our skill sets and organisation in sales. In working towards this goal and on an interim basis we have retained the services of Albert Sorrell who has 21 years experience in such roles with Medtronic Inc and Cochlear Ltd. Albert‘s prime task will be to help us achieve our immediate sales objectives, establish a cohesive sales and marketing organisation and define the role and profile of the person who will ultimately fill this role on a permanent basis. Albert will be working closely with everyone in the organisation and will report to the senior executive management team.”

Paul Butler, with responsibility for the day-to-day operations of the company reports to the Chief Executive, Mr Gary Davey.

Albert Sorrell brings to USCOM an essential set of skills and experience in devices sales and marketing, particularly in international distribution, having worked for a number of leading companies, including the Australian pioneer in ear implants, Cochlear and the US heart pacing giant, Medtronic.

USCOM also announced today an expansion of its Australian distribution network with the appointment of sales and applications representatives in Adelaide and Perth.

In addition, the company announced a significant expansion in the United States, where Nor’West Medical, based in Seattle, Washington, has been appointed as USCOM’s sales and distribution representative for the Pacific North West, covering the six states of Washington, Oregon, Alaska, Idaho, Utah and Montana.

At Sydney head office, USCOM has also appointed a new marketing administrator, Ms Jacinta Suprihat, whose role is to coordinate events and sales materials around the USCOM worldwide distribution and marketing network.

THREE NEW HOSPITALS ADOPT USCOM IN QUEENSLAND

March 29th, 2006

USCOM Limited (ASX Code: UCM) today announced the adoption of USCOM’s non-invasive cardiac output technology at three prestigious hospitals in Queensland.

The USCOM monitor has been ordered by the Royal Brisbane and Women’s Hospital, the Logan Hospital in Brisbane and the Beaudesert Hospital, each on a capital purchase basis.

USCOM will be used in clinical practice at Royal Brisbane’s Intensive Care department, while the machine will have a hospital-wide role at Logan, with particular focus on Emergency and Anaesthetics and in Emergency care at the Beaudesert hospital.

Today’s announcement brings to six the number of sites in Queensland where the USCOM device has been purchased and is in clinical practice. This includes the Queen Elizabeth II hospital in Brisbane and the important regional sites of Toowoomba, and Hervey Bay. In addition, USCOM is being used in significant research projects in the Intensive Care departments of the Princess Alexandra and Prince Charles Hospitals in Brisbane.

Commenting on the new Queensland installations, the Chief Executive of USCOM, Mr Gary Davey said, “This is highly significant news for USCOM. Both Royal Brisbane and Logan are key reference sites in Queensland and we are delighted to be working with them. USCOM is now being widely adopted by major teaching hospitals in Australia’s capital cities. We also continue to demonstrate the vital role we can play in the rural and regional health care sector across Australia, as shown in the commitment of Beaudesert hospital. It is important to note that our technology is being recognised across a wide range of applications, including critical care, emergency, surgery, retrieval and paediatrics. The USCOM machine has been designed for maximum flexibility across every department in the hospital.”

About Royal Brisbane

The Royal Brisbane and Women’s Hospital is a 942 bed tertiary referral teaching hospital, the largest in Queensland. The hospital provides services to patients throughout Queensland, Northern New South Wales, the Northern Territory and from neighbouring countries in the South West Pacific. The hospital fulfils a significant teaching and research role with links to Queensland’s major tertiary institutions. The hospital facilities have recently undergone a major redevelopment program with the majority of the two hospitals clinical services being rebuilt at a total cost of approximately $510 million making it the largest hospital redevelopment in Australia’s history.

About Logan

In the outer suburban area of Brisbane, Logan Hospital offers a broad range of health services in the catchment area of Queensland‘s fastest growing regional city. First constructed in 1990 as an 83 bed community hospital, Logan Hospital has undergone rapid growth reflecting the increasing population of Logan City. The hospital currently manages over 30,000 admissions annually.

About Beaudesert

The Beaudesert Hospital serves a rural district to the South West of Brisbane, offering a wide range of clinical services. Situated 40 kilometres to the West of the Gold Coast, Beaudesert is another high growth region of Southern Queensland where USCOM will be used in the hospital Emergency Department.

USCOM ACCURACY CONFIRMED.

March 24th, 2006

EUROPE CONFERENCE HEARS NEW EVIDENCE IN 2 STUDIES

Scientific research confirming the accuracy of USCOM was presented today in two separate studies at one of Europe’s most important medical conferences.

The two studies, one conducted at the Howard Florey Institute in Melbourne and the other at Royal Prince Alfred Hospital in Sydney, were presented at the 26th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium, attended by almost 5,000 clinicians from around the world.

Commenting on the two studies today, the Chief Executive of USCOM, Mr Gary Davey said, “For USCOM, the Brussels event is the most important of the year and it is great to have two papers being presented. Both are highly significant, particularly the compelling evidence that USCOM is more accurate than the gold standard method, not just in measuring cardiac output levels, but more importantly in tracking changes brought about by therapy. This is an extremely significant finding, We are delighted to be in the non-invasive sector of medical practice. This is especially true in paediatrics where we have been able to present further evidence for the role of USCOM.”

The Melbourne study conducted a direct 3-way comparison between USCOM, surgically implanted Flow Probes and the clinical “gold standard” method of the Pulmonary Artery Catheter (PAC). More than 800 measurements were taken from a series of sheep subjects at the Howard Florey medical research centre.

The study found extremely close agreement between USCOM and the highly sensitive Flow Probe method with a mean error of 5.5%. However, the mean error between Flow Probe and the Catheter was a clinically significant 20.4%.

In addition, the study assessed the ability of the 3 methods to measure changes in haemodynamics, altered by the induction of dobutamine, commonly used in the treatment of heart failure to increase cardiac function. The results suggest USCOM is significantly more sensitive to change than the invasive method.

The second study, conducted at Royal Prince Alfred Hospital in Sydney, supported USCOM’s role in the management of sick children. The study was designed to test the accuracy of the USCOM method of measuring blood flow through the hearts of pre-term neonates, ranging in size from 3.1 kilograms down to just 390 grams, with cardiac outputs from 0.12 to 1.61 Litres Per Minute.

Using the established Echocardiographic method (2D imaging and Doppler) for comparison, the study found no significant difference between the Echo and USCOM measurements, with a mean error between measurements of -3.7%. Importantly, the study also concluded, USCOM is an accurate method for measurement of neonatal cardiac output and may be more sensitive than conventional echo for the detection of haemodynamic change. USCOM is a simple, cost-effective alternative for neonatal haemodynamic management”.

Neonates Study Abstract (51kb)

Neonates Poster (1000kb)

Sheep Study Abstract (59kb)

Sheep Study Poster (1129kb)

REGULATORY APPROVAL IN TAIWAN

March 23rd, 2006

First sale secured in major new market

Budget provisions to purchase USCOM monitors indicated at key sites

USCOM Limited (ASX Code: UCM) today announced it had secured formal regulatory approval for the marketing of its non-invasive cardiac output monitor in Taiwan.

The approval comes in the form of an import license, issued by the Taiwan Department of Health.

USCOM’s distribution partner in Taiwan, Anson Health Care Limited, has already secured the first sale of an USCOM device, following regulatory approval. The USCOM machine has been sold to the Anaesthetics Department of the largest hospital in Taiwan, the 4,000 bed Chang Gung Memorial Hospital (CGMH) in Linkou, near the capital, Taipei. Across Taiwan, the CGMH group manages 6,800 hospital beds and serves 27000 out-patients per day.

With a population of almost 23 million, and one of the world’s strongest economies, Taiwan represents an important market for USCOM in North Asia.

Commenting on the announcement today, the Chief Executive of USCOM, Mr Gary Davey said, “Through our North Asia partner, Pacific Medical Systems, we have been working hard on Taiwan market entry. Anson and Pacific Medical have done a great job in representing USCOM through the regulatory process. This is an exciting market for us, with excellent feed-back from potential customers. We expect a lot of sales activity in Taiwan through 2006, having found a place on capital budget wish-lists at a number of key hospital sites.”

Click here to view Taiwan License (48kb pdf)

USCOM SPONSORS MEDICAL EDUCATION PROGRAMME IN U.S.

March 15th, 2006

A new education programme including USCOM’s role in emergency medicine has been launched in the United States.

The on-line educational symposium is now offered by the American College of Emergency Physicians (ACEP) under its Continuing Medical Education (CME) programme, where clinicians are awarded CME credits for having completed the course. Completion of this programme will award two hours of AMA Category 1 or two hours of ACEP Category 1 credit.

USCOM was, in part, the subject of an ACEP Satellite Symposium accredited by the Temple University School of Medicine. Titled, “Hemodynamic Assessment in the Emergency Department. Tools and Information for Clinical Decision Making”, the symposium was chaired by Robert Bilkovski MD, Senior Staff Physician at the Emergency Department, Henry Ford Hospital, Detroit. (Henry Ford is the home of the ground-breaking Rivers study which showed a 30% improvement in mortality rates through the implementation of Early Goal Directed Therapy in Emergency Care.)

Other speakers at the Satellite Symposium were:

H. Bryant Nguyen, MD, MS, Assistant Professor, Department of Emergency Medicine, Loma Linda University, Loma Linda, CA. Nathan Shapiro, MD, MPH, Research Director, Department of Emergency Medicine Staff Physician, Department of Emergency Medicine, Beth Israel Deaconess Hospital, Boston, MA. Rob Sherwin, MD, Assistant Professor of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI.

The overview to the Symposium stated:

“The need for hemodynamic assessment of patients in the Emergency Department is well acknowledged especially with the increased interest in Early Goal Directed Therapy (EGDT) for sepsis patients. However, widespread use of existing technologies and integration of the hemodynamic information gained from their use remains elusive in everyday practice. This program will provide an update to emergency physicians on currently available tools for hemodynamic monitoring and use of this information for decision making in Emergency Departments and transport patients.”

The symposium and on-line CME posting were supported by an unrestricted educational grant from USCOM.

Link to ACEP website

Download ACEP document (170kb)

TWO NEW SCIENTIFIC STUDIES

March 9th, 2006

USCOM:“simple, rapid, safe, well-tolerated and cost-effective”

USCOM Limited (ASX Code: UCM) today announced the release of significant new research into the accuracy of USCOM’s non-invasive cardiac output monitor at two Intensive Care Conferences in Japan and Europe.

In the first major presentation of USCOM evidence in Japan, a new study was released at the annual Japanese Society of Intensive Care Medicine Conference in Osaka.

The study was conducted among 47 patients in the Intensive Care Department of Tokyo’s Keio University Hospital, where clinicians compared USCOM to the invasive “gold standard” thermodilution catheter method of measuring cardiac output. The study was conducted among predominantly post cardiac surgery patients, representing a technical challenge for any measurement method.

The Keio University study, led by Dr Yoshifumi Kotake, found a mean difference between USCOM and the thermodilution method of 0.6 Litres per minute. The study found that the catheter measurement was routinely higher than the USCOM measurement, a difference which has been consistently born out in similar studies.

In a unique approach, Dr Kotake also compared 2 different methods of thermodilution (Continuous and Bolus) and found that the continuous catheter method routinely over-measured cardiac output when compared to the Bolus method, with a mean difference of 0.4 Litres per minute.

The study concluded that USCOM, as a method of measuring cardiac output is clinically acceptable, especially when its non-invasiveness is taken into account.

Commenting on the new study today, the Chairman of USCOM, Mr Rob Phillips said, “This is an important milestone toward clinical adoption in Japan. Dr Kotake’s work has shed significant new light on the existing invasive methods, which are now under intense review worldwide. We are working on more collaborative studies with clinicians in Japan and we look forward to an exciting future in the Japanese market, the second largest in the world.”

Meanwhile, a study among 25 ventilated ICU patients at a teaching hospital in the Netherlands has also produced good correlation between USCOM and thermodilution catheters. The study concluded that:

The study, at Gelderse Vallei Hospital, Ede, The Netherlands, was conducted by 10 clinicians and nurses who recorded more than 1,300 USCOM measurements. The study demonstrated good inter-operator and inter-patient variability. In addition, the study also showed using the USCOM device on shock patients, clinicians could make the same clinical decisions as with the thermodilution catheter, with the added advantage of USCOM being non-invasive. Like the Tokyo study, the Netherlands results also showed a consistent over-measurement of cardiac output by the Pulmonary Artery Catheter method.

Results were presented at the Netherlands Society of Intensive Care Conference.

Click here for Netherlands Study – pdf(261kb)

MILESTONE IN CHILDREN’S SECTOR, USCOM NOW AT 8 LEADING PAEDIATRICS SITES

March 8th, 2006

USCOM Limited (ASX Code: UCM) today announced the sale of USCOM cardiac output monitors to two important children’s medical sites in Asia.

The latest paediatrics sites to adopt USCOM in clinical practice are the Shenzhen Children’s Hospital in Southern China and the Saitama Paediatrics Hospital in Tokyo.

Today’s announcement brings to 6 the number of new USCOM paediatrics sites to be installed in recent weeks.

The company had previously installed USCOM machines at the neonatology department of the Mercy Hospital in Melbourne, at two major Children’s Hospitals in the U.S. and the Duchess of Kent Children’s Hospital in Hong Kong.

In addition, the company’s technology is in use at a number of other paediatrics centres of excellence, including the Great Ormond Street Hospital in London and the University Hospital of Zurich, an important European centre for paediatric and neonatal medicine.

The role of USCOM in paediatrics has been the subject of several scientific studies. The most recent being a study at the neonatal intensive care department of the Vanderbilt Children’s Hospital in Nashville, Tennessee, one of the most prestigious children’s medical sites in the United States.

The purpose of the study was to investigate intra-user variability and the time necessary to obtain USCOM measurements. The study concluded “With low intra-user variability and an average measurement time of less than 2 minutes, the USCOM device proves to be a practical method of assessing cardiac status in a pediatric critical care setting.“ The Vanderbilt study was presented at the Pediatric Cardiac Intensive Care Society Symposium in Miami, Florida in December 2005.

Commenting on today’s announcement, the Chief Executive of USCOM, Mr Gary Davey said, “Our eight paediatrics sites are all centres of excellence in the care of children and we are very excited about the potential growth for USCOM in this important sector. It is great to see our technology being used on a day-to-day basis in the treatment of children. We believe USCOM will become a standard of care in paediatrics and neonatology around the world.”

MULTICENTRE GLOBAL STUDY, 7 hospitals collaborate

February 2nd, 2006

USCOM Limited (ASX Code: UCM) today announced a multi-centre, international research collaborative between some of the most respected academic Emergency Departments (ED) and Intensive Care Units (ICU) in the world. The collaboration is centred in the Henry Ford Hospital Emergency Department in Detroit, and, will be focused on developing the science of non-invasive haemodynamic management using the USCOM device.

The international collaborative brings together seven practice leading Emergency and Intensive Care Departments, including;

Each of these sites is currently using the USCOM device in clinical practice. The collaboration creates the opportunity to rapidly define the role of USCOM in clinical management of circulation by bringing together world leaders in the field to focus on methods of improving critical care management of haemodynamics.

Dr Bob Bilkovski from Henry Ford Hospital in Detroit said “We believe this international collaboration has the potential to define and improve clinical practice in critical care medicine worldwide. An international collaboration is particularly exciting, and increases the opportunity of producing important outcomes and changes to practice.”

The Australian arm of the project is being led by Dr Paul Middleton and Dr Sally McCarthy of the Prince of Wales Hospital in Sydney.

Dr Middleton said “We are delighted with this formal relationship with USCOM and the chance to broaden our research into cardiovascular function in critical illness. We look forward to developing techniques that may improve the way emergency medicine is practiced. The International collaboration is an exciting way to develop our vision of emergency care within a global model.”

Commenting on the study today, the Chairman of USCOM Limited, Mr Rob Phillips said, “This is extremely exciting for us because this work will define the role of USCOM in EDs and ICUs around the world. The collaboration of such a highly credible group will certainly lead to changes in clinical care and we look forward to seeing the research outcomes of this powerful international relationship. While we are already working with academics, opinion leaders and early adopters around the world, this type of influential collaboration is necessary to drive USCOM into global general practice.”

SYSTEM UPDATE RELEASE - 14 PARAMETERS OF CARDIAC FUNCTION NOW AVAILABLE

February 1st, 2006

USCOM Limited (ASX Code: UCM) today announced the release of important new advancements, in both software and hardware, to the USCOM non-invasive cardiac output monitor.

Among the system enhancements is the addition of four new parameters of cardiac function, taking to 14 the number of parameters now available for display on the USCOM monitor. The USCOM display has also been enhanced to allow the user to select from three different screen formats, with 4, 6 or 9 real-time parameters on display

In addition, today’s release incorporates a new “instant on” mode for use in emergency situations and an advanced function for saving groups of heart beats, further enhancing the utility of USCOM across a wide range of clinical applications.

Along with the latest software upgrade, USCOM today released an advanced new design of its ultrasound transducer, providing enhanced performance and greater ergonomics. The latest design incorporates a clip-on handle, improving ease-of-use and operator comfort. The new USCOM transducer represents the state-of-the-art in ultrasonics and manufacture. Using specialist materials, such as Kevlar lined cables, the new hardware delivers superior performance in signal-to-noise ratio and further protects the USCOM system from unwanted signal interference.

Commenting on the release today, the Chairman of USCOM Limited, Mr Rob Phillips said, USCOM is committed to a coordinated programme of continual advancement to its technology. In many ways, this is the most significant system upgrade we have released, providing enhancements in both software and hardware, as well as offering the capacity to customise the system display. This is an important step forward for the company and we are proud of the achievements we continue to make in the evolution of the USCOM technology.”

The following is a summary of each of the new functions, released today.

4 NEW PARAMETERS:

The additional parameters now available for display are:

FT

Flow Time. The period, measured in milliseconds during which blood is flowing through the heart valves

SVI

Stroke Volume Index

SVV

Stroke Volume Variability

SVRI

Systemic Vascular Resistance Index

Click to view complete list of USCOMs 14 parameters of cardiac function

QUICK START This is a new function allowing for “instant on” operation and eliminating the need for the entry of patient information. By selecting the “RUN” button on the opening screen, the operator is taken direct to the Examination screen and the ultrasound transducer is automatically activated. This is an extremely important function whenever time is of the essence, such as in an Emergency Department where clinicians need rapid assessment. The information can be recorded in the normal way and made complete with the later addition of patient details, including height and weight for the calculation of some cardiac output parameters.

CUSTOM CARDS With 14 different parameters of cardiac function now available on the USCOM system, it is no longer possible to effectively display all the measures on one screen. The new software enables the operator to select from three different display lay-outs and provides for customisation of the display with 4, 6 or 9 measurements. For example, the operator may choose just 4 priority measures for display. This allows for a more prominent presentation of the information. At the same time, all 14 parameters are available instantly at the touch of a button.

GROUP SAVE Until now, each heart beat has been measured one-at-a-time. With the system, the operator can chose to save ONE beat, ALL beats displayed or a selected GROUP of beats. With the ALL function selected, each beat on the screen is automatically traced and ready for saving as individual cards. This provides for very rapid assessment of average measurements.

NEW ADVANCED TRANSDUCERS Along with the latest software upgrade, USCOM today released an advanced new design of its ultrasound transducer, providing enhanced performance and greater ergonomics. The new design allows for improved access to the patient’s acoustic windows and enhances signal clarity through advanced shielding techniques. With a wider focal range, the new USCOM transducer is suitable for both adult and paediatric patients. As a major technical advancement to the existing USCOM ultrasonics system, the new technology requires no additional training and is compatible with all existing USCOM monitors. With a custom designed detachable handle, the new transducer is easier and more comfortable to use, the product of the very latest in ergonomic design.

USCOM FOR THE MANAGEMENT OF SEPSIS IN CHILDREN

January 12th, 2006

USCOM Limited (ASX Code: UCM) ) today announced the presentation of an important new paper, further defining the role of USCOM in the management of sepsis among children.

The paper was presented by Dr Joe Brierley of Great Ormond St Hospital for Children in London at the 35th Society of Critical Care Medicine Critical Care Congress in San Francisco.

Severe sepsis is a serious and increasingly common disease of adults and children, which is frequently fatal. Appropriate haemodynamic management of these patients has been demonstrated to save lives. Dr Brierley’s work demonstrates that USCOM can be used to select the appropriate treatment for these often difficult-to-manage children by accurately evaluating their haemodynamics. The findings suggest that the benefits may also be demonstrated in adults.

Commenting on the study today, the Chairman of USCOM Limited, Mr Rob Phillips said, “This is extremely exciting for us because this work suggests a critical role for USCOM in the management of sepsis in children in EDs and ICUs around the world. Sepsis is an extremely serious condition for adults and children and improvements in haemodynamic management will save lives and resources. This is an important role for USCOM.”

Sepsis affects 18 million people worldwide every year, and costs more than $US22,000 per case to treat. Approximately 750,000 new severe sepsis cases present each year in the United States alone with an approximately 10% mortality in children and 30% in adults. The results of this study improve our understanding of the disease, and have ramifications for future diagnosis, treatments and research.

Click here for Abstract – PDF (52kb)